- Record: found
- Abstract: found
- Article: not found
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
Jennifer C C Hu
1 ,
Robert S Coffin ,
Ceri J Davis ,
Nicola J Graham ,
Natasha Groves ,
Peter J Guest ,
Kevin J Harrington ,
Nicholas D James ,
Colin A Love ,
Iain McNeish ,
Louise C Medley ,
Agnieszka Michael ,
Christopher M Nutting ,
Hardev S Pandha ,
Claire A Shorrock ,
Julie Simpson ,
Jan Steiner ,
Neil M Steven ,
Dennis Wright ,
R Charles Coombes
Nov 15 2006
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To conduct a phase I clinical trial with a second-generation oncolytic herpes simplex virus (HSV) expressing granulocyte macrophage colony-stimulating factor (Onco VEXGM-CSF) to determine the safety profile of the virus, look for evidence of biological activity, and identify a dosing schedule for later studies.